報價延遲最少15分鐘:2025/07/17 16:44 EDT
盤後時段
|
||||
|
22.01 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
22.01
|
|
|
| 價值評估 |
|
盈利(現時/預測)
1.70/43.96
|
|
企業價值
13.58B
|
| 資產負債 |
|
每股賬面淨值
8.61
|
| 現金流量 |
|
現金流量率
0.08
|
| 損益表 |
|
收益
21.53B
|
|
每股收益
3.92
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/17 16:44 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications. |
